Articles from Octave

Octave, an innovator in outcomes-focused behavioral health care, today announced the launch of WiseMatch by Octave, a proprietary technology platform that modernizes insurance directories and makes it easier for patients to find and book in-network mental health care.

Drawing on decades of expertise, the potential Hexagon spin-off helps organizations navigate uncertainty and manage change across the world’s most critical infrastructure

Octave, a leading neuroscience precision care company that delivers a new standard for managing multiple sclerosis (MS) and other neurodegenerative diseases, today announced the presentation of new data on its MS-specific MRI Insights Program, Clinical Insights Program, and Protein Biomarker Program at the Consortium of Multiple Sclerosis Centers (CMSC) Annual Meeting 2023. The data adds to the growing evidence supporting all dimensions of the company’s comprehensive Precision Care Solution for MS.

Octave, a leading digital health sciences company that delivers a new standard for managing multiple sclerosis (MS) and other neurodegenerative diseases, today announced the presentation of nine abstracts at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Conference 2023. The abstracts, presented in partnership with several of Octave’s premier research partners, included data on the company’s MRI Insights program as well as applications of the company’s clinically-validated Multiple Sclerosis Disease Activity (MSDA) test, including real-world data as well as new deep scan proteomic approaches. Research collectively underscored the strength and utility of the company’s Precision Care Solution for MS, which commercially launched in October 2022 and delivers quantitative, objective insights to better characterize individual patients’ underlying biology, response to therapeutic interventions, radiographic status, and evolving symptoms.

Octave, a leading digital health sciences company that delivers a new standard for managing multiple sclerosis (MS) and other neurodegenerative diseases, today announced the presentation of data from 13 abstracts presented at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Conference 2022. The posters and presentations collectively reinforce the company’s Precision Care Solution, adding to the analytical and clinical validation of the novel MS Disease Activity (MSDA) Test, highlighting progress in the development of a first-of-its-kind disease progression biomarker test, and providing new data around the proprietary MRI Insights component of the solution.

Octave, a leading digital health sciences company that delivers a new standard for managing multiple sclerosis (MS) and other neurodegenerative diseases, today announced that its precision care solution for MS is now commercially available. Octave’s Solution introduces quantitative, objective measures to help transform care from a field driven by subjective, qualitative metrics. Through its multidimensional approach, the solution provides deeper insights into individual patients’ underlying biology, radiographic status, and ongoing symptomology. By creating and delivering novel tools and services, Octave provides actionable insights about patients that can lead to better outcomes.

Octave, the developer of a fully-integrated precision care solution built to deliver comprehensive insights that bring scientific clarity to multiple sclerosis (MS), announced data focused on the company’s novel MS Disease Activity (MSDA) test. The data was shared in a poster presentation at the Consortium of Multiple Sclerosis Centers (CMSC) 2022 Annual Meeting.

Octave, the developer of a fully-integrated Precision Care Solution built to deliver comprehensive insights that bring scientific clarity to multiple sclerosis (MS), today announced the presentation of data based on eight posters at the ACTRIMS Forum 2022. The posters collectively support the upcoming launch of the company’s Precision Care Solution, with seven of the posters focused on the company’s novel MS Disease Activity (MSDA) test including clinical validation study results and independent cohort replication.